Literature DB >> 16505976

Determination of a human hepatic microsomal scaling factor for predicting in vivo drug clearance.

Nancy Hakooz1, Kiyomi Ito, Helen Rawden, Helen Gill, Lynn Lemmers, Alan R Boobis, Robert J Edwards, David J Carlile, Brian G Lake, J Brian Houston.   

Abstract

PURPOSE: To determine a microsomal scaling factor for human liver suitable for prediction of in vivo drug clearance from in vitro data and to explore the role of inter-liver variability in this factor on the reported underprediction from microsomal parameters.
METHODS: Cytochrome P450 (henceforth P450) content in whole homogenates and microsomes from 38 donor livers was used to determine a microsomal scaling factor. In a subset (n = 20) of these preparations, individual P450 enzymes were examined by Western blotting and selective probe activities were determined.
RESULTS: The scaling factor from 38 livers averaged 40 mg microsomal protein per gram liver with a coefficient of variation of 31%. Western blotting experiments indicated that there was no P450 enzyme-specific trend in the distribution of individual P450 enzymes in liver microsomes relative to whole homogenate. Predictions based on an average scaling factor resulted in a satisfactory prediction of intrinsic clearance of three benzodiazepines similar to that obtained using individual factors for the same livers.
CONCLUSION: A value for human liver microsomal scaling of 40 mg microsomal protein per gram liver has been established. The reason for underprediction previously reported for 52 different drug substrates was not the use of an incorrect value for the scaling factor.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16505976     DOI: 10.1007/s11095-006-9531-2

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  27 in total

Review 1.  Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data.

Authors:  T Iwatsubo; N Hirota; T Ooie; H Suzuki; N Shimada; K Chiba; T Ishizaki; C E Green; C A Tyson; Y Sugiyama
Journal:  Pharmacol Ther       Date:  1997       Impact factor: 12.310

2.  THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. I. EVIDENCE FOR ITS HEMOPROTEIN NATURE.

Authors:  T OMURA; R SATO
Journal:  J Biol Chem       Date:  1964-07       Impact factor: 5.157

3.  Comparison of the use of liver models for predicting drug clearance using in vitro kinetic data from hepatic microsomes and isolated hepatocytes.

Authors:  Kiyomi Ito; J Brian Houston
Journal:  Pharm Res       Date:  2004-05       Impact factor: 4.200

4.  Cytochrome P-450 measurement in rat liver homogenate and microsomes. Its use for correction of microsomal losses incurred by differential centrifugation.

Authors:  J G Joly; C Doyon; Y Peasant
Journal:  Drug Metab Dispos       Date:  1975 Nov-Dec       Impact factor: 3.922

5.  Variance of Microsomal Protein and Cytochrome P450 2E1 and 3A Forms in Adult Human Liver.

Authors:  John C Lipscomb; Linda K Teuschler; Jeffrey C Swartout; Cynthia A F Striley; John E Snawder
Journal:  Toxicol Mech Methods       Date:  2003       Impact factor: 2.987

6.  Identification of cytochrome P-450 isoforms responsible for cis-tramadol metabolism in human liver microsomes.

Authors:  V Subrahmanyam; A B Renwick; D G Walters; P J Young; R J Price; A P Tonelli; B G Lake
Journal:  Drug Metab Dispos       Date:  2001-08       Impact factor: 3.922

7.  Microsomal prediction of in vivo clearance and associated interindividual variability of six benzodiazepines in humans.

Authors:  H C Rawden; D J Carlile; A Tindall; D Hallifax; A Galetin; K Ito; J B Houston
Journal:  Xenobiotica       Date:  2005-06       Impact factor: 1.908

8.  Effects of age and gender on in vitro properties of human liver microsomal monooxygenases.

Authors:  D L Schmucker; K W Woodhouse; R K Wang; H Wynne; O F James; M McManus; P Kremers
Journal:  Clin Pharmacol Ther       Date:  1990-10       Impact factor: 6.875

9.  In vivo pharmacokinetics of felodipine predicted from in vitro studies in rat, dog and man.

Authors:  C Bäärnhielm; H Dahlbäck; I Skånberg
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1986-08

10.  Microsomal cytochrome P-450-linked monooxygenase systems and lipid composition of human hepatocellular carcinoma.

Authors:  I Hamamoto; S Tanaka; T Maeba; K Chikaishi; Y Ichikawa
Journal:  Br J Cancer       Date:  1989-01       Impact factor: 7.640

View more
  16 in total

Review 1.  Applications of human pharmacokinetic prediction in first-in-human dose estimation.

Authors:  Peng Zou; Yanke Yu; Nan Zheng; Yongsheng Yang; Hayley J Paholak; Lawrence X Yu; Duxin Sun
Journal:  AAPS J       Date:  2012-03-10       Impact factor: 4.009

2.  Prediction of human metabolic clearance from in vitro systems: retrospective analysis and prospective view.

Authors:  David Hallifax; Joanne A Foster; J Brian Houston
Journal:  Pharm Res       Date:  2010-07-27       Impact factor: 4.200

3.  Interlaboratory Variability in Human Hepatocyte Intrinsic Clearance Values and Trends with Physicochemical Properties.

Authors:  Christine M Bowman; Leslie Z Benet
Journal:  Pharm Res       Date:  2019-05-31       Impact factor: 4.200

4.  Integrated Gut and Liver Microphysiological Systems for Quantitative In Vitro Pharmacokinetic Studies.

Authors:  Nikolaos Tsamandouras; Wen Li Kelly Chen; Collin D Edington; Cynthia L Stokes; Linda G Griffith; Murat Cirit
Journal:  AAPS J       Date:  2017-07-27       Impact factor: 4.009

5.  Prediction of Drug Clearance from Enzyme and Transporter Kinetics.

Authors:  Priyanka R Kulkarni; Amir S Youssef; Aneesh A Argikar
Journal:  Methods Mol Biol       Date:  2021

6.  In vitro-in vivo extrapolation of CYP2C8-catalyzed paclitaxel 6α-hydroxylation: effects of albumin on in vitro kinetic parameters and assessment of interindividual variability in predicted clearance.

Authors:  Nitsupa Wattanachai; Thomas M Polasek; Tahlia M Heath; Verawan Uchaipichat; Wongwiwat Tassaneeyakul; Wichittra Tassaneeyakul; John O Miners
Journal:  Eur J Clin Pharmacol       Date:  2011-02-09       Impact factor: 2.953

7.  Neonatal development of hepatic UGT1A9: implications of pediatric pharmacokinetics.

Authors:  Shogo J Miyagi; Alison M Milne; Michael W H Coughtrie; Abby C Collier
Journal:  Drug Metab Dispos       Date:  2012-04-05       Impact factor: 3.922

8.  Mass spectrometry-based quantification of CYP enzymes to establish in vitro/in vivo scaling factors for intestinal and hepatic metabolism in beagle dog.

Authors:  Aki T Heikkinen; Arno Friedlein; Jens Lamerz; Peter Jakob; Paul Cutler; Stephen Fowler; Tara Williamson; Roberto Tolando; Thierry Lave; Neil Parrott
Journal:  Pharm Res       Date:  2012-02-22       Impact factor: 4.200

9.  Characterization of increased drug metabolism activity in dimethyl sulfoxide (DMSO)-treated Huh7 hepatoma cells.

Authors:  S Choi; B Sainz; P Corcoran; S Uprichard; H Jeong
Journal:  Xenobiotica       Date:  2009-03       Impact factor: 1.908

10.  Quantitative ADME proteomics - CYP and UGT enzymes in the Beagle dog liver and intestine.

Authors:  Aki T Heikkinen; Arno Friedlein; Mariette Matondo; Oliver J D Hatley; Aleksanteri Petsalo; Risto Juvonen; Aleksandra Galetin; Amin Rostami-Hodjegan; Ruedi Aebersold; Jens Lamerz; Tom Dunkley; Paul Cutler; Neil Parrott
Journal:  Pharm Res       Date:  2014-07-18       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.